CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes

Mandaviya lays foundation stone for NCDC regional branch, state branches and 2 BSL-3 laboratories

Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India

Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs

Healthcare Triangle completes US$2 million private placement debt offering

The company received gross proceeds of approximately US$1.7 million and net proceeds,

Inspira Technologies closes on $3.88 million RDO

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering

Sun Pharma to acquire 16.7% stake in Lyndra Therapeutics for $30 mn

According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)